| Domingo B Gumpal, | |
|
296 W Hawaii St, Kahului, HI 96732-2610 | |
| (808) 873-8802 | |
| Not Available |
| Full Name | Domingo B Gumpal |
|---|---|
| Gender | Male |
| Speciality | Social Worker - Clinical |
| Location | 296 W Hawaii St, Kahului, Hawaii |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124154356 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 1547 (Hawaii) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Domingo B Gumpal, 296 W Hawaii St, Kahului, HI 96732-2610 Ph: () - | Domingo B Gumpal, 296 W Hawaii St, Kahului, HI 96732-2610 Ph: (808) 873-8802 |
News Archive
Focusing on a rare but devastating complication in patients with single-ventricle heart disease, a research team has revealed the role of leakage from the liver's lymphatic system, and used a novel procedure to seal off those leaks and improve symptoms in patients.
Miglustat is a drug currently under phase 2 clinical trials on patients suffering from cystic fibrosis (1). Its potential for treating the disease was discovered in 2006 thanks to the work of Frédéric Becq's team at the Institute of Cell Physiology and Biology (CNRS/Université de Poitiers), funded by the associations Vaincre la Mucoviscidose, MucoVie66, La Pierre Le Bigaut and ABCF2.
Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company's lead product candidate, ENV515 (travoprost XR).
A study published today in the journal Science shows how our bodies try to minimise potential 'collateral damage' caused by our immune system when fighting infection. The research may also provide new clues to why cigarette smoke is a significant risk factor for developing diseases of the lung such as chronic bronchitis and emphysema.
Novo Nordisk announced today that the company will establish a type 1 diabetes research and development center in Seattle, Wash., U.S. The new center will combine Novo Nordisk's history of innovation and leadership in diabetes treatment with the company's growing expertise in immunotherapy.
› Verified 8 days ago
Margo Rowland, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 48 Lono Ave, Kahului, HI 96732 Phone: 808-871-7772 Fax: 808-871-8540 | |
Ms. Nicole Naulani Galindo, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 135 Wakea Ave., #101, Kahului, HI 96732 Phone: 808-268-9410 | |
David J Mckinley, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 333 Dairy Rd, Suite 201, Kahului, HI 96732 Phone: 808-877-6888 Fax: 808-877-6860 | |
Mrs. Noreen Joyce, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 135 S Wakea Ave, Ste 101, Kahului, HI 96732 Phone: 808-572-9439 | |
Madeline Colon, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 360 Hoohana St Ste 207, Kahului, HI 96732 Phone: 813-815-1170 | |
Ms. Monica Young Borge, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 340 Molokai Hema St, Kahului, HI 96732 Phone: 808-269-6547 |